More recent studies have suggested that the σ2R is a potential target as a disease-modifying therapy in Alzheimer’s disease by preventing the binding of Aβ oligomers to binding sites on neurons [15,26]. This evidence concerns the gene TMEM97 and early-onset autosomal dominant Alzheimer disease.